|
1,893
|
| 14493 |
APOE (isoform E3)
|
|
decreases_quantity of
|
amyloid beta deposits
|
|
| 14555 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
HDL
|
in human fibroblasts
|
| 14557 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
ABCA1
|
|
|
20170744
|
|
7,250
|
| 71309 |
APOE (isoform E3)
|
|
increases_expression of
|
APP
|
compared to ApoE2
|
| 71324 |
APOE (isoform E3)
|
|
increases_activity of
|
Abeta (42) secretion
|
in human neurons cultured on MEFs ; compared to ApoE2
|
| 71325 |
APOE (isoform E3)
|
|
increases_activity of
|
Abeta (40) secretion
|
in human neurons cultured on MEFs ; compared to ApoE2
|
| 71344 |
APOE (isoform E3)
|
|
increases_activity of
|
MAP3K12
|
in human neurons; compared to ApoE2;
via binding to ApoE receptors
|
| 71365 |
APOE (isoform E3)
|
NOT |
affects_activity of
|
Alzheimer disease
|
if human neurons are cultured on mouse glia;
|
| 124908 |
APOE (isoform E3)
|
|
decreases_expression of
|
APP
|
compared to ApoE4
|
| 124912 |
APOE (isoform E3)
|
|
decreases_activity of
|
Abeta (42) secretion
|
in human neurons cultured on MEFs ; compared to ApoE4
|
| 124913 |
APOE (isoform E3)
|
|
decreases_activity of
|
Abeta (40) secretion
|
in human neurons cultured on MEFs ; compared to ApoE4
|
| 124916 |
APOE (isoform E3)
|
|
decreases_activity of
|
MAP3K12
|
in human neurons; compared to ApoE4;
via binding to ApoE receptors
|
| 124918 |
APOE (isoform E3)
|
|
increases_quantity of
|
Amyloid beta peptide (42)
|
compared to ApoE2; unrelated to alpha-or beta-secretase expression
|
| 124919 |
APOE (isoform E3)
|
|
increases_quantity of
|
Amyloid beta peptide (40)
|
compared to ApoE2; unrelated to alpha-or beta-secretase expression
|
| 124920 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (42)
|
compared to ApoE4; unrelated to alpha-or beta-secretase expression
|
| 124921 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (40)
|
compared to ApoE4; unrelated to alpha-or beta-secretase expression
|
|
28111074
|
|
7,255
|
| 71370 |
APOE (isoform E3)
|
|
increases_activity of
|
triglyceride-rich lipoprotein particle clearance
|
|
| 71385 |
APOE (isoform E3)
|
|
decreases_activity of
|
abnormal lipid level
|
|
| 71415 |
APOE (isoform E3)
|
|
increases_activity of
|
normal lipid level
|
|
| 114525 |
APOE (isoform E3)
|
|
decreases_activity of
|
very-low-density lipoprotein particle binding
|
ApoE4 binds much better than apoE3 to VLDL
|
|
25328986
|
|
7,522
|
| 74189 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
AR
|
in cortical extracts; in Apo-/- mice
|
|
18395206
|
|
7,868
|
| 78408 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (42, soluble)
|
extracellular, in the hippocampus and cortex of ovariectomized female EFAD mice, treated for 3 months with 17- estradiol
|
| 102082 |
APOE (isoform E3)
|
|
affects_activity of
|
Estradiol
|
in ovariectomized EFAD mice treated with estradiol; extracellular amyloid plaque and Abeta deposition is decreased with APOE2 and APOE3
|
| 102085 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (soluble)
|
in ovariectomized EFAD mice treated with estradiol
|
|
24368217
|
|
8,038
|
| 79572 |
APOE (isoform E3)
|
|
increases_activity of
|
extended life span
|
for APOE3 haplotype (ATTTC) if associated with HRAS1/RASSF7 haplotype (CGCGCGT) and LASS1/CERS1 haplotypes (CCT and CGT)
|
| 79907 |
RASSF7
|
|
increases_activity of
|
APOE (isoform E3)
|
for HRAS1/RASSF7 haplotype (CGCGCGT) if associated with APOE3 haplotype (ATTTC) and LASS1 haplotypes (CCT and CGT)
|
| 79909 |
CERS1
|
|
increases_activity of
|
APOE (isoform E3)
|
for LASS1/CERS1 haplotype (CGT and CCT) if associated with APOE3 haplotype (ATTTC) and HRAS1/RASSF7 haplotype (CGCGCGT)
|
|
20569235
|
|
8,566
|
| 88065 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased circulating cholesterol level
|
Parallel study, 5wk of fat spread with or without (1.1 or 2.2 g/d) PS diet,
n=217 hypercholesterolemic M and F;
Ethnicity=Spanish; Lower TC, LDL-C, TC/HDL-C, and LDL-C/HDL-C ratios in E2 and E3 carriers with PS vs placebo intake;
|
| 88066 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased circulating LDL cholesterol level
|
Parallel study, 5wk of fat spread with or without (1.1 or 2.2 g/d) PS diet,
n=217 hypercholesterolemic M and F;
Ethnicity=Spanish; Lower TC, LDL-C, TC/HDL-C, and LDL-C/HDL-C ratios in E2 and E3 carriers with PS vs placebo intake;
|
| 88067 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased circulating cholesterol/HDL ratio
|
Parallel study, 5wk of fat spread with or without (1.1 or 2.2 g/d) PS diet,
n=217 hypercholesterolemic M and F;
Ethnicity=Spanish; Lower TC, LDL-C, TC/HDL-C, and LDL-C/HDL-C ratios in E2 and E3 carriers with PS vs placebo intake;
|
| 88068 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased circulating LDL/HDL cholesterol ratio
|
Parallel study, 5wk of fat spread with or without (1.1 or 2.2 g/d) PS diet,
n=217 hypercholesterolemic M and F;
Ethnicity=Spanish; Lower TC, LDL-C, TC/HDL-C, and LDL-C/HDL-C ratios in E2 and E3 carriers with PS vs placebo intake;
|
| 88071 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased circulating HDL cholesterol level
|
Crossover study, 4wk of SFA followed by low-fat/high-CHO or MUFA intake diet,
n=84 healthy young M and F,
Ethnicity=Spanish; Lower in E3/2 F with CHO or MUFA
intake vs E3/3 and
E4/3 carriers;
|
| 88073 |
APOE (isoform E3)
|
|
increases_activity of
|
increased circulating LDL cholesterol level
|
Crossover study, 6wk of wholegrain
wheat or white bread (2 servings/d)
intake diet;
n=28 M and F (14
NGI and 14 HGI),
Ethnicity=Not specified; Higher in E3/E3 NGI carriers with whole grain vs white bread
intake;
|
| 88074 |
APOE (isoform E3)
|
|
increases_activity of
|
increased circulating cholesterol/HDL ratio
|
Crossover study, 6wk of wholegrain
wheat or white bread (2 servings/d)
intake diet;
n=28 M and F (14
NGI and 14 HGI),
Ethnicity=Not specified; Higher TG/HDL-C ratio in E3/3 HGI carriers with whole-grain vs white bread
intake;
|
|
26117841
|
|
9,062
|
| 94820 |
APOE (isoform E3)
|
|
increases_activity of
|
triglyceride binding
|
in Glycogen storage disease Ia patients
|
| 94822 |
APOE (isoform E3)
|
|
increases_activity of
|
triglyceride-rich lipoprotein particle clearance
|
in Glycogen storage disease Ia patients
|
|
10801051
|
|
9,068
|
| 95563 |
APOE rs429358
|
|
affects_quantity of
|
APOE (isoform E3)
|
together with rs7412
|
| 95566 |
APOE rs7412
|
|
affects_quantity of
|
APOE (isoform E3)
|
together with rs429358
|
| 95569 |
APOE3-p.112C-158R
|
|
increases_activity of
|
APOE (isoform E3)
|
|
| 95575 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
LDLR
|
apoE3 and apoE4 bind similarly to LDLR, while apoE2 has 50‚Äď100 times lower binding affinity
|
| 95583 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
HDL
|
in plasma
|
| 113327 |
APOE (isoform E3)
|
|
increases_activity of
|
high-density lipoprotein particle binding
|
in plasma; apoE2 and apoE3 prefer high-density lipoprotein (HDL),
|
| 113328 |
APOE (isoform E3)
|
|
increases_activity of
|
low-density lipoprotein particle binding
|
in plasma; apoE4 is usually associated with very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL)
|
| 113339 |
APOE (isoform E3)
|
|
increases_activity of
|
low-density lipoprotein particle receptor binding
|
apoE3 and apoE4 bind similarly to LDLR, while apoE2 has 50‚Äď100 times lower binding affinity
|
|
27328687
|
|
9,095
|
| 95366 |
APOE (isoform E3)
|
|
decreases_expression of
|
IRS2
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95370 |
APOE (isoform E3)
|
|
decreases_expression of
|
IGF1
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95371 |
APOE (isoform E3)
|
|
decreases_expression of
|
SLC2A4
|
in female mouse brain (hippocampus); protein analysis showed significantly decreased Igf1, Irs, and Glut4 in ApoE3 brain compared to APOE2
|
| 95373 |
APOE (isoform E3)
|
|
decreases_activity of
|
glucose import
|
in female mouse brain; compared to APOE2
|
| 95379 |
APOE (isoform E3)
|
|
decreases_expression of
|
IRS1
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95394 |
APOE (isoform E3)
|
|
decreases_expression of
|
RRAS2
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95401 |
APOE (isoform E3)
|
|
decreases_expression of
|
BRAF
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95402 |
APOE (isoform E3)
|
|
decreases_expression of
|
CEBPB
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95404 |
APOE (isoform E3)
|
|
decreases_expression of
|
MAPK1
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95405 |
APOE (isoform E3)
|
|
decreases_expression of
|
PIK3CB
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95406 |
APOE (isoform E3)
|
|
decreases_expression of
|
PRKCI
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95407 |
APOE (isoform E3)
|
|
decreases_expression of
|
PRKCG
|
in female mouse brain (hippocampus); compared to APOE2
|
| 95408 |
APOE (isoform E3)
|
|
increases_expression of
|
AKT1
|
in female mouse brain; compared to APOE2
|
| 95420 |
APOE (isoform E3)
|
|
increases_expression of
|
AKT2
|
in female mouse brain; compared to APOE2
|
| 95421 |
APOE (isoform E3)
|
|
increases_expression of
|
GRB2
|
in female mouse brain; compared to APOE2
|
| 95427 |
APOE (isoform E3)
|
|
increases_expression of
|
LDLR
|
in female mouse brain; compared to APOE2
|
| 95428 |
APOE (isoform E3)
|
|
increases_expression of
|
PCK2
|
in female mouse brain; compared to APOE2
|
| 95429 |
APOE (isoform E3)
|
|
increases_expression of
|
PIK3R2
|
in female mouse brain; compared to APOE2
|
| 95430 |
APOE (isoform E3)
|
|
increases_expression of
|
PKLR
|
in female mouse brain; compared to APOE2
|
| 126264 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased SLC2A4 expression
|
in APOE3 middle-aged female mouse brain
|
| 126268 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased IRS1 expression
|
in APOE3 middle-aged female mouse brain
|
|
26402005
|
|
9,096
|
| 95774 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
MAPT
|
ApoE3 rather than ApoE4 mainly interacts with MAPT/TAU.
|
| 124926 |
APOE (isoform E3)
|
|
decreases_activity of
|
Amyloid beta peptide (oligomer)
|
compared to APOE4
|
|
30032423
|
|
9,098
|
| 95859 |
APOE (isoform E3)
|
|
decreases_expression of
|
VAMP2
|
in female mouse brain; 15% decrease in synaptobrevin2 expression in ApoE3 animals compared with ApoE2 animals
|
| 109550 |
APOE (isoform E3)
|
|
increases_activity of
|
ESR2
|
enhancing ERbeta activity could provide a greater therapeutic benefit for ApoE2 and ApoE3 carriers than for ApoE4 carriers
|
|
28934977
|
|
9,101
|
| 126342 |
APOE (isoform E3)
|
|
decreases_expression of
|
SLC2A4
|
in female middle-aged APOE3 mouse brains; compared to APOE2 brains
|
| 126343 |
APOE (isoform E3)
|
|
decreases_expression of
|
HK2
|
in female middle-aged APOE3 mouse brains; compared to APOE2 brains
|
| 126347 |
APOE (isoform E3)
|
|
increases_expression of
|
HK2
|
in female middle-aged APOE3 mouse brains; compared to APOE4 brains
|
| 126348 |
APOE (isoform E3)
|
|
increases_expression of
|
HK1
|
in female middle-aged APOE3 mouse brains; compared to APOE4 brains
|
| 126349 |
APOE (isoform E3)
|
|
increases_expression of
|
SLC2A3
|
in female middle-aged APOE3 mouse brains; compared to APOE4 brains
|
| 126351 |
APOE (isoform E3)
|
|
decreases_expression of
|
DLAT
|
in ApoE3 brain; compared to APOE2
|
| 126352 |
APOE (isoform E3)
|
|
increases_expression of
|
PGD
|
in ApoE3 brain; compared to APOE4
|
| 126355 |
APOE (isoform E3)
|
|
decreases_expression of
|
BDH1
|
in ApoE3 brain; compared to APOE2
|
| 126356 |
APOE (isoform E3)
|
|
decreases_expression of
|
SLC16A1
|
in ApoE3 brain of middle-aged female mice; compared to APOE2
|
| 126357 |
APOE (isoform E3)
|
|
decreases_expression of
|
HK2
|
in APOE3 brain ; compared to APOE2
|
| 126358 |
ketogenic agent AC-1202
|
|
increases_activity of
|
APOE (isoform E3)
|
in APOE3 carriers
|
| 126382 |
APOE (isoform E3)
|
|
increases_expression of
|
PPARGC1A
|
in ApoE3 brains; compared to ApoE4
|
| 139432 |
APOE (isoform E3)
|
NOT |
affects_expression of
|
SLC2A1
|
in Apoe3 brain of middle-aged female mice; concerning the mRNA, no significant difference in GLUT1 expression among the three ApoE genotypes was detected
|
|
29967007
|
|
9,222
|
| 98135 |
APOE (isoform E3)
|
|
decreases_activity of
|
APOE (isoform E4)
|
|
|
28461186
|
|
10,777
|
| 110194 |
APOE (isoform E3)
|
|
increases_activity of
|
apolipoprotein E recycling
|
compared to ApoE3
|
|
26564908
|
|
10,849
|
| 110847 |
APOE (isoform E3)
|
|
increases_activity of
|
high-density lipoprotein particle binding
|
compared to APOE4
|
| 110910 |
APOE (isoform E3)
|
|
increases_activity of
|
APOE lipidation
|
compared to APOE4
|
| 120735 |
APOE (isoform E3)
|
|
increases_activity of
|
APOE3 lipidation
|
compared to APOE4; deficient lipid binding and transport by APOE4 might therefore be expected to result in widespread brain abnormalities
|
|
30804776
|
|
10,915
|
| 111169 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Proinflammatory cytokine
|
removing APOE can lead to a more pro-inflammatory phenotype
|
| 111212 |
APOE (isoform E3)
|
|
decreases_expression of
|
IGF1
|
in aged mice expressing either APOE4 or APOE3; compared to APOE2 mice
|
| 111214 |
APOE (isoform E3)
|
|
decreases_expression of
|
IRS1
|
in aged mice expressing either APOE4 or APOE3; compared to APOE2 mice
|
| 111216 |
APOE (isoform E3)
|
|
decreases_expression of
|
SLC2A4
|
in aged mice expressing either APOE4 or APOE3; compared to APOE2 mice
|
|
30804776
|
|
10,947
|
| 111884 |
TREM2
|
|
affects_activity of
|
APOE (isoform E3)
|
via APOE3-binding (binding reduced by the mutant TREM2-p.R47H)
|
|
26374899
|
|
11,172
|
| 112934 |
APOE (isoform E3)
|
|
increases_activity of
|
low-density lipoprotein particle receptor binding
|
compared to APOE2
|
|
31640095
|
|
11,213
|
| 113195 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
HDL
|
while APOE3 and APOE2 preferentially bind HDL, APOE4 rather associates with VLDL particles
|
| 113197 |
APOE (isoform E3)
|
|
increases_activity of
|
high-density lipoprotein particle binding
|
while APOE3 and APOE2 preferentially bind HDL, APOE4 rather associates with VLDL particles
|
| 113202 |
APOE (isoform E3)
|
|
increases_activity of
|
low-density lipoprotein particle receptor binding
|
compared to APOE2
|
| 113211 |
APOE (isoform E3)
|
|
increases_activity of
|
antioxidant effect
|
APOE4 is a poorer antioxidant compared with APOE3 and APOE2
|
|
27457486
|
|
11,517
|
| 114949 |
APOE (isoform E3)
|
|
increases_activity of
|
SYNJ1 mRNA catabolic process
|
ApoE3 degrades synj1 mRNA rapidly
|
| 114950 |
APOE (isoform E3)
|
NOT |
affects_activity of
|
SYNJ1 protein catabolic process
|
synj1 protein degradation rates are comparable between different ApoE isoforms
|
| 114981 |
APOE (isoform E3)
|
|
increases_activity of
|
RNA catabolic process
|
ApoE3 degrades synj1 mRNA rapidly, whereas ApoE4 fails to do so
|
|
26372964
|
|
11,536
|
| 115081 |
APOE (isoform E3)
|
|
increases_activity of
|
low-density lipoprotein particle receptor binding
|
compared to apoB100 and APOE2
|
| 140652 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
LDLR
|
compared to apoB100 and APOE2
|
|
27277824
|
|
12,016
|
| 117728 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (40)
|
ApoE3 reduced Abeta40 by 60-80%
|
| 117731 |
APOE (isoform E3)
|
|
decreases_quantity of
|
Amyloid beta peptide (42)
|
ApoE3 reduced Abeta42 by 20-30%
|
| 117735 |
APOE (isoform E3)
|
|
decreases_activity of
|
Gamma-secretase complex
|
ApoE3 reduces gamma-secretase cleavage of APP, lowering secreted Abeta levels; probabely via the lipid-binding domain of apoE
|
|
15312168
|
|
12,104
|
| 118850 |
APOE (isoform E3)
|
|
increases_activity of
|
SOD
|
in oxidative stress damaged cerebral cortical neurons
|
|
29272008
|
|
12,309
|
| 120638 |
Amyloid beta peptide (soluble)
|
|
interacts (colocalizes) with
|
APOE (isoform E3)
|
Abeta is an extremely poor binding partner of APOE isoforms
|
| 120705 |
APOE (isoform E3)
|
|
interacts (colocalizes) with
|
Amyloid beta peptide (soluble)
|
in the cerebrospinal fluid of human subjects, producing apoE3 and apoE4 isoforms; but only a minimal interaction, independently of APOE isoform
|
|
23620513
|
|
12,310
|
| 124976 |
APOE (isoform E3)
|
|
increases_activity of
|
amyloid-beta clearance
|
in hamster ovarian cells; compared to cells secreting apoE4
|
| 124977 |
APOE (isoform E3)
|
|
decreases_activity of
|
amyloid-beta clearance
|
in hamster ovarian cells; compared to cells secreting apoE2
|
|
23620513
|
|
12,322
|
| 143366 |
APOE (isoform E3)
|
|
is_part_of
|
APOE3-Abeta complex
|
|
|
27470930
|
|
12,370
|
| 121796 |
APOE (isoform E3)
|
|
decreases_activity of
|
Schizophrenia
|
in an Asian population
|
|
30814349
|
|
12,519
|
| 121860 |
APOE (isoform E3)
|
|
increases_activity of
|
liver fibrosis
|
in male and female Caucasian Italian patients with HCV; patients not carrying an APOE3 allele, as well as carriers of a single APOE3 allele with serum cholesterol concentration >190 mg/dL were more likely to have a favorable outcome regarding fibrosis progression with HCV
|
| 121875 |
APOE (isoform E3)
|
|
increases_activity of
|
Hepatitis C, chronic
|
in male and female Caucasian Italian patients with HCV; patients not carrying an APOE3 allele, as well as carriers of a single APOE3 allele with serum cholesterol concentration >190 mg/dL were more likely to have a favorable outcome regarding fibrosis progression with HCV
|
|
30814349
|
|
12,522
|
| 121910 |
APOE (isoform E3)
|
|
increases_activity of
|
decreased episodic memory
|
in young, healthy persons; compared with APOE4
|
|
28335828
|
AlzNet-DB